Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

COAG

Hemab Therapeutics Holdings Inc

May 29 • 04:00PM ET

28.50

+0.50 1.79 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: LABT VBIO ABVE ABVC ACET AARD AAPG ABEO ABOS ABCL

| Held by: TMSL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	30.43%	Shs Outstand	46.71M	Perf Week	8.37%
Market Cap	1.33B	Forward P/E	-	EPS next Y	-2.38	Insider Trans	25.67%	Shs Float	32.49M	Perf Month	-
Enterprise Value	1.53B	PEG	-	EPS next Q	-	Inst Own	32.75%	Short Float	2.34%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	96.04%	Inst Trans	-72.88%	Short Ratio	1.73	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	11.30%	ROA	-	Short Interest	0.76M	Perf YTD	-16.18%
Book/sh	-4.25	P/C	8.14	EPS next 5Y	64.71%	ROE	-	52W High	36.61 -22.15%	Perf Year	-
Cash/sh	3.50	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	23.00 23.91%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.32% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.91	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.85	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.35	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.85	EPS Q/Q	-	SMA20	5.50%	Beta	-	Target Price	41.75
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	5.50%	Rel Volume	0.28	Prev Close	28.00
Employees	72	LT Debt/Eq	-	Earnings	-	SMA200	5.50%	Avg Volume	438.29K	Price	28.50
IPO	May 01, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	123,057	Change	1.79%

Date	Action	Analyst	Rating Change	Price Target Change
May-26-26	Initiated	Wedbush	Outperform	$42
May-26-26	Initiated	Jefferies	Buy	$39
May-26-26	Initiated	Goldman	Buy	$36
May-26-26	Initiated	Evercore ISI	Outperform	$50

May-27-26 08:00AM	Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-26 07:00AM	Hemab Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-04-26 04:01PM	Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -25.47%

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded on February 12, 2026 and is headquartered in Cambridge, MA.

Ph.D.Dr. Benny Sorensen M.D.

CFO & GMMr. Mads Nikolaj Behrndt-Eriksen M.Sc.

Chief Medical OfficerDr. Catherine Eilleen Madigan M.D.

Ph.D.Dr. Ananthram Sreenivasa Murthy M.Sc.

Senior Vice President of CMC & ManufacturingMs. Cecile Bonvoisin M.Sc.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 19 '26	Buy	24.97	3,802	94,936	6,375,972	May 21 04:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 20 '26	Buy	24.94	996	24,840	6,376,968	May 21 04:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 12 '26	Buy	24.90	6,387	159,036	6,372,170	May 14 05:21 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 11 '26	Buy	24.81	39,869	989,226	6,365,783	May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 07 '26	Buy	24.46	9,906	242,323	6,324,431	May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 08 '26	Buy	24.98	1,483	37,045	6,325,914	May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 04 '26	Buy	18.00	2,675,000	48,150,000	6,149,096	May 06 07:16 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 05 '26	Buy	24.63	97,411	2,399,546	6,246,507	May 06 07:16 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 06 '26	Buy	24.60	68,018	1,673,399	6,314,525	May 06 07:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COAG

Hemab Therapeutics Holdings Inc

Upgrade your Finviz experience